Pubblicazioni

Autori:

Levaggi, Rosella; Pertile, Paolo

Titolo:

Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

ISSN Rivista:

1175-5652

N° Volume:

18

Numero o Fascicolo:

3

Intervallo pagine:

455-456-456

Parole chiave:

value based prices; pharmaceutical regulation

Breve descrizione dei contenuti:

Personalised drugs will increase the heterogeneity in patients’ responses to treatment; this opens new scenarios with regard to the relationship between price regulation and listing strategies by the industry. In a static framework, if the effectiveness differential across patients can be observed only by the manufacturer, the main definitions currently proposed for value-based prices lead to the same listing strategy. This is no longer true in a dynamic setting where competition by a new entrant is possible. To predict accurately the implications of alternative pricing policies, it is essential for decision makers to adopt a dynamic perspective that takes the role of competition into account.

Id prodotto:

115040

Handle IRIS:

11562/1020030

ultima modifica:

15 novembre 2022

Citazione bibliografica:

Levaggi, Rosella; Pertile, Paolo, Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" «APPLIED HEALTH ECONOMICS AND HEALTH POLICY» , vol. 18 , n. 3 , 2020 , pp. 455-456-456

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo